Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
Atea Pharmaceuticals (AVIR) has appointed Arthur S. Kirsch to its Board of Directors, effective immediately. Kirsch brings decades of experience in investment banking, capital markets, and extensive knowledge of healthcare and life sciences industries. He currently serves as a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group and has previously held key positions at various global investment banks over his 30-year career.
The appointment aims to strengthen Atea's board as the company advances its strategic priorities, particularly in exploring partnerships for its Phase 3 program involving the combination of bemnifosbuvir and ruzasvir for hepatitis C virus treatment. Kirsch's experience in executing strategic advisory assignments and various public and private financings is expected to contribute to enhancing shareholder value.
Atea Pharmaceuticals (AVIR) ha nominato Arthur S. Kirsch nel suo Consiglio di Amministrazione, con effetto immediato. Kirsch porta con sé decenni di esperienza nel settore della banca d'investimento, dei mercati dei capitali e una vasta conoscenza delle industrie sanitarie e delle scienze della vita. Attualmente ricopre il ruolo di Senior Advisor nel gruppo Life Sciences di Alvarez & Marsal e ha precedentemente ricoperto posizioni chiave in diverse banche d'investimento globali nel corso della sua carriera trentennale.
La nomina mira a rafforzare il consiglio di Atea mentre l'azienda avanza nelle sue priorità strategiche, in particolare nell'esplorare partnership per il suo programma di Fase 3 che coinvolge la combinazione di bemnifosbuvir e ruzasvir per il trattamento dell'epatite C. Si prevede che l'esperienza di Kirsch nell'esecuzione di incarichi di consulenza strategica e in vari finanziamenti pubblici e privati contribuisca ad aumentare il valore per gli azionisti.
Atea Pharmaceuticals (AVIR) ha nombrado a Arthur S. Kirsch en su Junta Directiva, con efecto inmediato. Kirsch aporta décadas de experiencia en banca de inversión, mercados de capitales y un amplio conocimiento de las industrias de salud y ciencias de la vida. Actualmente se desempeña como Asesor Senior en el Grupo de Ciencias de la Vida de Alvarez & Marsal y ha ocupado anteriormente cargos clave en varios bancos de inversión globales a lo largo de su carrera de 30 años.
El nombramiento tiene como objetivo fortalecer la junta de Atea mientras la empresa avanza en sus prioridades estratégicas, particularmente en la exploración de asociaciones para su programa de Fase 3 que involucra la combinación de bemnifosbuvir y ruzasvir para el tratamiento del virus de la hepatitis C. Se espera que la experiencia de Kirsch en la ejecución de asignaciones de asesoría estratégica y en diversos financiamientos públicos y privados contribuya a aumentar el valor para los accionistas.
Atea Pharmaceuticals (AVIR)는 Arthur S. Kirsch를 이사회의 일원으로 즉시 임명했습니다. Kirsch는 투자은행, 자본시장 분야에서 수십 년의 경험과 의료 및 생명과학 산업에 대한 광범위한 지식을 가지고 있습니다. 그는 현재 Alvarez & Marsal의 생명과학 산업 그룹에서 수석 고문으로 활동하고 있으며, 30년 경력 동안 여러 글로벌 투자은행에서 주요 직책을 역임했습니다.
이번 임명은 Atea가 전략적 우선 사항을 추진하는 가운데 이사회를 강화하기 위한 것으로, 특히 C형 간염 치료를 위한 bemnifosbuvir와 ruzasvir의 조합을 포함한 3상 프로그램을 위한 파트너십 탐색에 집중하고 있습니다. Kirsch의 전략적 자문 과제 수행 및 다양한 공공 및 민간 자금 조달 경험이 주주 가치를 높이는 데 기여할 것으로 기대됩니다.
Atea Pharmaceuticals (AVIR) a nommé Arthur S. Kirsch au sein de son Conseil d'Administration, avec effet immédiat. Kirsch apporte des décennies d'expérience dans le secteur de la banque d'investissement, des marchés des capitaux, ainsi qu'une vaste connaissance des industries de la santé et des sciences de la vie. Il est actuellement Conseiller Senior au sein du groupe des Sciences de la Vie d'Alvarez & Marsal et a précédemment occupé des postes clés dans diverses banques d'investissement mondiales au cours de sa carrière de 30 ans.
Cette nomination vise à renforcer le conseil d'Atea alors que l'entreprise fait progresser ses priorités stratégiques, notamment en explorant des partenariats pour son programme de Phase 3 impliquant la combinaison de bemnifosbuvir et ruzasvir pour le traitement du virus de l'hépatite C. L'expérience de Kirsch dans l'exécution de missions de conseil stratégique et dans divers financements publics et privés devrait contribuer à accroître la valeur pour les actionnaires.
Atea Pharmaceuticals (AVIR) hat Arthur S. Kirsch mit sofortiger Wirkung in seinen Vorstand berufen. Kirsch bringt Jahrzehnte an Erfahrung im Investment Banking, im Kapitalmarkt und umfassendes Wissen über die Gesundheits- und Lebenswissenschaftsbranchen mit. Derzeit ist er als Senior Advisor in der Life Sciences Industry Group von Alvarez & Marsal tätig und hat zuvor in seiner 30-jährigen Karriere Schlüsselpositionen in verschiedenen globalen Investmentbanken innegehabt.
Die Ernennung zielt darauf ab, den Vorstand von Atea zu stärken, während das Unternehmen seine strategischen Prioritäten vorantreibt, insbesondere bei der Erkundung von Partnerschaften für sein Phase-3-Programm, das die Kombination von bemnifosbuvir und ruzasvir zur Behandlung des Hepatitis-C-Virus umfasst. Kirschs Erfahrung in der Durchführung strategischer Beratungsaufträge und verschiedenen öffentlichen und privaten Finanzierungen wird voraussichtlich dazu beitragen, den Shareholder Value zu steigern.
- Addition of board member with extensive M&A and capital markets experience
- Strategic expertise could help advance Phase 3 program partnerships
- Potential enhancement of company's ability to execute strategic transactions
- None.
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company’s Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries.
Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acquisitions and equity capital markets at global investment banks. Over that time, he executed a wide range of strategic advisory assignments for clients in the healthcare and life sciences industries as well as numerous public and private financings.
"We are very pleased to have Arthur join our Board of Directors. His extensive financial and strategic advisory experience will further strengthen the Atea Board as we advance our strategic priorities,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea. "Arthur’s proven track record of executing and overseeing transactions will be invaluable as we pursue opportunities to enhance shareholder value, including the exploration of strategic partnerships related to our Phase 3 program, the combination of bemnifosbuvir and ruzasvir, a potentially best-in-class regimen for the treatment of hepatitis C virus."
Since July 2019, Mr. Kirsch has served as a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group. From June 2005 until June 2019, Mr. Kirsch served as a Managing Director and Senior Advisor for GCA Global, LLC, a global investment banking firm. From May 1994 to May 2004, he served as Head of Research at Vector Securities, LLC, a brokerage firm. Prior to that, Mr. Kirsch served as CEO of NatWest Securities Limited, where he was responsible for managing the global securities business. Mr. Kirsch began his career at Drexel Burnham Lambert, Inc., an investment banking firm.
Mr. Kirsch serves on the Board of Directors of Liquidia Technologies, Inc. (Nasdaq: LQDA). He previously served on the Board of Kadmon Holdings, Inc. (NYSE: KDMN), where he was a member of the Transaction Committee involved in overseeing its sale to Sanofi, as well as Immunomedics, POZEN Inc. and Aralez, Inc.
Mr. Kirsch received his B.A. in Finance from the University of Rhode Island and earned his MBA in Finance from Bernard M. Baruch College.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, to treat hepatitis C virus. For more information, please visit
www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the contributions of Mr. Kirsch to the Atea Board of Directors and Atea’s opportunities to enhance shareholder value. When used herein, words including “expected,” “should,” “anticipated,” “believe.” “will,” “plans”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea’s current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption “Risk Factors” in Atea’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
barnes.jonae@ateapharma.com
Tim McCarthy
LifeSci Advisors
+1 917-679-9282
tim@lifesciadvisors.com
FAQ
What is the significance of Arthur Kirsch joining AVIR's board of directors?
What is AVIR's Phase 3 program focusing on?
What is Arthur Kirsch's current role outside of AVIR?
How might Arthur Kirsch's appointment impact AVIR's strategic direction?
